Skip to main content
Caplight Logo









hema.to

hema.to

Private
MunichHealthcare & Life Scienceshttps://www.hema.to/

Last Round

Seed

Feb 27, 2025

Total Funding Raised

$7.71M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

hema.to is a medtech company that provides a cloud-based software-as-a-service (SaaS) platform using artificial intelligence to automate the analysis of blood data for diagnostic support.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Healthcare Analytics, Vertical SaaS, Precision Medicine

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

flow cytometryclinical flow cytometrydiagnostic supportmedical AIpathology AIhematology softwareflow cytometry analysisCE-IVDworkflow automationB2B SaaSprecision medicinedigital pathologyautomated gatinglab informaticsmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

hema.to Comparables

Compare hema.to with similar companies based on industry and business-model similarity.

hema.to comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AHEAD Medicine
90%
FlowView Diagnostics BV
85%
METAFORA Biosystems
82%

hema.to Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 27, 2025
SeedJun 26, 2023

Key People

Founding team and executive leadership

Felix Kunzweiler

Co-Founder & CTO

Founding Team

Karsten Miermans

Chief Executive Officer

Executive Team

Daniel Moritz

Interim Chief Financial Officer

Executive Team

hema.to Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 312% MoM.

  • Feb 27, 2025

    $4M round led by LUMO Labs

hema.to Filings

Explore SEC and related filing metadata, where available.

hema.to filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about hema.to's valuation, stock price, and market status.

Is hema.to a public or private company?

hema.to is a private company.

What is the current stock price of hema.to?

hema.to is a private company with no public stock price. No recent secondary market data is available.

How much is hema.to worth (valuation)?

Valuation information for hema.to is not publicly available.

Can I buy hema.to stock?

hema.to shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was hema.to's last funding round?

hema.to's most recent funding round was Seed on February 27, 2025.

Who are the main investors in hema.to?

Key investors in hema.to include LUMO Labs, Elaia Partners, Heal Capital.

Will hema.to IPO soon?

No public IPO plans have been announced for hema.to.

How can I track hema.to secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor hema.to's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMunich
Employee Range17
Year Founded2021
Last FundingFeb 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?